摘要
目的:探讨131I治疗Craves病(GD)的最佳剂量方法并分析其中影响疗效的因素。方法:155例GD患者按最佳公式计算131I剂量。治疗前后进行示踪和治疗剂量的甲状腺摄碘率(TUR)和有效半衰期(EHL)测量,甲状腺重量采用显像(RI)及B超(US)重复测量。结果:131I治疗前后24hTUR和EHL综合影响为1.08。甲状腺重量下降率与治疗前重量关系呈弱正相关。临床治愈率为71.0%、未愈为29.0%。TGAb、TMAb阳性与阴性组比较正常、甲减和未愈均有差异。结论:GD131I疗效受不同给药方法的影响,甲状腺重量是最重要的一个参数。治疗前后TUR和EHL综合影响为1.08。甲状腺抗体在甲减的发生、发展过程中起一定的作用。迅速控制甲亢,而又要降低甲减率,难以兼顾。
Objective：The aim of this object was intended to optimize radiation dose for iodine-131 to treatment Graves＇ disease （GD）and analyzed possible factors affect outcome.Methods：155 patients with GD were selected. Determined 131I tracer thyroid uptake（TUR）＆ effective half-life（EHL）.Thyroid weight was estimated by radionuclide imaging（RI）＆ ultrasound （US）before ＆after 131I therapy repeat examined. The TUR＆EHL of 131I therapy dose.Thyroid function was determined by serum＆ thyroid antibody.Results：The TUR ,EHL of tracer dose＆therapeutic, were lower 1.04×1.04=1.08.the thyroid weigh of the patients repeat after 131I treatment was significantly decreased. Followed up, 110 patient appeared euthyroid 71.0%,23 became latent hypothyroidism 14.8%,45 were still hyperthyroidism.TGAb （TMAb）positive were difference ne- gitiveive.Conclusion： There are facts affects 131I therapy：the formulas of calculations is choice.Thyroid weight are main factor. The TUR＆EHL of therapeutic are lower than racer dose,if 1.08 use to correct the dose of therapeutic dose, persistent hyperthyroidism will reduce in this object ;TGAb （TMAb）playis some role in hypothyroidism development; actual dose of 131I solution＆capsule is discrepancy from expect dose.Used 131I dose calculated by optimize formula to treatment Graves＇ disease ,but it was difficult to control hyperthyroidism in all patients ＆avoid hypothyroidism.
出处
《中国医药导报》
CAS
2008年第18期17-19,共3页
China Medical Herald
